December 8-10, Houston, USA

Meet DiaCarta Team at The Bladder & Kidney

Cancer Academy 2022

Press Release

DiaCarta to Become a Publicly Listed Company

Through Merger with HH&L Acquisition Co.

Press Release

DiaCarta Receives CE-IVD Mark for Its

SARS-CoV-2 Flu A/B Combo Test

Press Release

DiaCarta’s Multivariant COVID-19 Test

Accurately Detects the Omicron Variant

Media Coverage by Genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay

to Gauge Chemotherapy Response

in Multiple Cancers

December 8-10, 2022, Houston

Meet DiaCarta Team at the Bladder & Kidney Cancer Academy 2022

Press Release

DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co.

Press Release

DiaCarta Receives CE-IVD Mark for Its SARS-CoV-2 Flu A/B Combo Test

Press Release

DiaCarta’s Multivariant COVID-19 Test Accurately Detects the Omicron Variant

Media Coverage by genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay to Gauge Chemotherapy Response in Multiple Cancers

DiaCarta is a leading translational genomics and personalized diagnostics company based in Pleasanton, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies that will change the landscape of precision medicine and molecular diagnostics by impacting healthcare treatment plans and the well-being of individuals around the world.

HPV mRNA Screening

NGS Targeted Sequencing

CLIA Lab Service

ULTRA-SENSITIVE

XNA Technology

XNA, xenonucleic acids, are innovative new nucleic acid molecular oligomers that hybridize by Watson-Crick base pairing to target DNA sequences, and yet have a modified chemical backbone. XNA oligomers are highly effective at hybridizing to targeted normal DNA sequences and can be employed as molecular clamps in quantitative real-time polymerase chain reactions (qPCR) or as highly specific molecular probes for the detection of nucleic acid target sequences. The XNA tightly binds to the wild-type sequence that is 100% complementary and blocks DNA polymerase from DNA elongation; only the mutant target sequence gets amplified because the XNA:mutant DNA duplex is not stable due to mismatch and fall off from the template in PCR reactions.

ULTRA-SENSITIVE

SuperBDNA™ Technology

SuperbDNA™ technology uses branched DNA to qualitatively or quantitatively measure the presence of target DNA or RNA. Unlike PCR or RT-PCR, SuperbDNA™ technology does not amplify the DNA or RNA in the samples, rather amplifies the signals for detection. Because the amplified signal is proportional to the levels of the target (DNA or RNA) in the samples, the latter is easy to be quantified with a standard curve. SuperbDNA™ technology has been used in FDA-approved clinical applications, including prognosis and monitoring of patients with viral diseases. 

DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co.

DiaCarta, Ltd., a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, and HH&L Acquisition Co. (NYSE: HHLA.U, HHLA, HHLA WS) (“HH&L”), a publicly traded special purpose acquisition company (“SPAC”), today announced that they entered into a definitive business combination agreement (the “Business Combination Agreement”) that is expected to result in DiaCarta becoming a publicly listed company (the “Transaction” or “Business Combination”). The Transaction is expected to provide DiaCarta with access to the approximately $414 million cash from HH&L’s IPO proceeds held in trust, assuming no redemptions by HH&L’s shareholders and prior to the payment of transaction expenses, and potential additional financing to catalyze DiaCarta’s growth. The Transaction implies a pre-money equity value of $460 million for DiaCarta on a fully diluted basis and is expected to close in the first quarter of 2023. The Transaction positions DiaCarta to capitalize on significant future growth within existing and new markets.

Early Cancer Detection Will Save More Lives

linkedinfacebooktwitterCancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone....

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X